SCM
CEROW

Segantii Capital Management’s CERo Therapeutics Warrants CEROW Stock Holding History

Segantii Capital Management’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,000
Closed -$55K – 121
2023
Q4 		$55K Hold
5,000
– – ﹤0.01% 144
2023
Q3 		$54.3K Hold
5,000
– – ﹤0.01% 162
2023
Q2 		$54.5K Hold
5,000
– – ﹤0.01% 183
2023
Q1 		$53.4K Hold
5,000
– – ﹤0.01% 306
2022
Q4 		$51K Hold
5,000
– – ﹤0.01% 403
2022
Q3 		$50K Hold
5,000
– – ﹤0.01% 542
2022
Q2 		$50 Hold
5,000
– – ﹤0.01% 544
2022
Q1 		$50K Hold
5,000
– – ﹤0.01% 597
2021
Q4 		$50K Buy
+5,000
New +$2.31K ﹤0.01% 578

Other funds holding CEROW

HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return

Segantii Capital Management's CEROW Position: Q1 2024 in Review

Segantii Capital Management sold out of CERo Therapeutics Warrants (CEROW) in Q1 2024, closing a stake of 5,000 shares — an estimated $55K sold.

Segantii Capital Management first reported a position in CEROW in Q4 2021 and held it in 9 quarters. The position peaked at $55K in Q4 2023. 37 funds tracked by Wall St. Rank hold CEROW as of Q1 2024.

  • Segantii Capital Management reported no remaining CERo Therapeutics Warrants position as of Q1 2024 after selling out during the quarter.
  • Segantii Capital Management sold 5,000 CERo Therapeutics Warrants shares in Q1 2024, an estimated $55K.
  • Segantii Capital Management first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 9 quarters.
  • Segantii Capital Management's CERo Therapeutics Warrants position peaked at $55K in Q4 2023.
  • 37 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q1 2024.

Based on Segantii Capital Management's 13F filing for Q1 2024, filed 14 May 2024.